SLXNW · Insider Trading
Silexion Therapeutics Corp Warrant
Every open-market purchase and sale reported by SLXNW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-08 | Hadar Mirit Horenshtein | CFO and Secretary | A | +7,500 | — |
| 2026-06-08 | Mitchell Shirvan | CSO and CDO | A | +6,000 | — |
| 2026-06-08 | Ilan Hadar | Chairman and CEO | A | +10,000 | — |
| 2026-03-30 | Mitchell Shirvan | CSO and CDO | Sell | −22,818 | −$31.03K |
| 2026-02-25 | Shlomo Noy | Director | A | +9,091 | — |
| 2026-02-23 | Dror Yosef Abramov | Director | A | +9,091 | — |
| 2026-02-23 | Ilan Hadar | Chairman and CEO | A | +64,350 | — |
| 2026-02-23 | Ruth Alon | Director | A | +9,091 | — |
| 2026-02-23 | Mitchell Shirvan | CSO and CDO | A | +49,726 | — |
| 2026-02-23 | Hadar Mirit Horenshtein | CFO and Secretary | A | +49,726 | — |
| 2026-02-23 | Amnon Peled | Director | A | +7,576 | — |
| 2026-02-23 | Avner Lushi | Director | A | +9,091 | — |
| 2026-01-27 | Ilan Levin | Director | MIXED | +888,900 | +$3.60M |
| 2025-12-31 | Avner Lushi | Director | A | +1,587 | — |
| 2025-12-31 | Dror Yosef Abramov | Director | A | +794 | — |
| 2025-12-31 | Ruth Alon | Director | A | +794 | — |
| 2025-12-31 | Amnon Peled | Director | A | +661 | — |
| 2025-12-31 | Shlomo Noy | Director | A | +1,587 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Ilan Levin | Director | 456,970 | $4.57K |
| Shlomo Noy | Director | 25,399 | $254 |
| Avner Lushi | Director | 25,399 | $254 |
| Ilan Hadar | Chairman and CEO | 16,547 | $165 |
| Hadar Mirit Horenshtein | CFO and Secretary | 12,515 | $125 |
| Ruth Alon | Director | 10,228 | $102 |
| Dror Yosef Abramov | Director | 10,180 | $102 |
| Mitchell Shirvan | CSO and CDO | 8,789 | $88 |
| Amnon Peled | Director | 8,237 | $82 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SLXNW quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.